Figure 6
Figure 6. Representative histology of tumors in hVEGF-D TG mice. Images were taken from HE-stained or immunohistochemically stained paraffin sections of mouse tissues and analyzed with Olympus Provis AX70 Microscope attached to Olympus ColorView 12 Camera. The software for imaging and analyses was AnalySIS (Soft Imaging System). (A) Mammary adenocarcinoma with a predominantly solid growth pattern showed focal ducts. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (B) Higher magnification of the solid part of mammary carcinoma shown in panel A with atypical cells and a few mitotic figures. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (C) Mammary adenocarcinoma with a solid growth pattern displaying only single remnants of ducts. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (D) Higher magnification of the solid part of mammary carcinoma shown in panel C with atypical cells and a few mitotic figures. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (E) Mammary adenocarcinoma showing a tubular growth pattern. Bar. 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (F) Higher magnification of the carcinoma shown in panel E showing both tubular and solid areas. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (G) Well-differentiated mammary adenocarcinoma showing a tubular growth pattern. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (H) Higher magnification of the carcinoma shown in panel G. Bar, 50 μm. (I) Immunostaining for hVEGF-D was positive in the surface of ductular structures. Picture from carcinoma is shown in panels E and F. Bar, 100 μm. The objective lens used was UPlanApo 10×/0.4 Ph1 ∞/0.17 (Olympus). (J) Solid parts of tumor shown in panels E and F showed CK7 immunopositivity. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (K) Increased number of vessels with angiogenic features in mammary adenocarcinoma shown in panels C and D. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (L) Lung with metastases of mammary adenocarcinoma. Original tumor shown in panels E and F. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (M) Higher magnification of the lung metastasis shown in panel L. Note dilated ducts. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (N) Lung papillary adenocarcinoma. Bar, 50 μm. (O) Higher magnification of the adenocarcinoma papillae in tumor shown in panel N. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (P) Positive immunostaining for hVEGF-D in papilla stalk. Note positivity also in vessels at the border of the tumor. Bar, 100 μm. The objective lens used was UPlanApo 10×/0.4 Ph1 ∞/0.17 (Olympus). (Q) Multifocal foci of bronchioloalveolar proliferation in lung adenocarcinoma. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (R) Higher magnification of the bronchioloalveolar proliferation in adenocarcinoma shown in panel R. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (S) Solid growth in skin basal cell carcinoma. Note necrosis. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (T) Higher magnification of the basal cell carcinoma. Note mitosis. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (U) Skin anaplastic carcinoma consists of spindle cells. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (V) Higher magnification of the anaplastic carcinoma. Note atypia. Bar, 50 μm. The objective lens used UPlanApo 20×/0.70 (Olympus). (W) Some tumor cells were positive for hVEGF-D immunostaining in an anaplastic carcinoma. Bar, 100 μm. The objective lens used was UPlanApo 10×/0.4 Ph1 ∞/0.17 (Olympus). (X) Increased number of vessels with angiogenic features in an anaplastic carcinoma shown in panels U and V. Bar, 100 μm. The objective lens used was UPlanApo 10×/0.4 Ph1 ∞/0.17 (Olympus).

Representative histology of tumors in hVEGF-D TG mice. Images were taken from HE-stained or immunohistochemically stained paraffin sections of mouse tissues and analyzed with Olympus Provis AX70 Microscope attached to Olympus ColorView 12 Camera. The software for imaging and analyses was AnalySIS (Soft Imaging System). (A) Mammary adenocarcinoma with a predominantly solid growth pattern showed focal ducts. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (B) Higher magnification of the solid part of mammary carcinoma shown in panel A with atypical cells and a few mitotic figures. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (C) Mammary adenocarcinoma with a solid growth pattern displaying only single remnants of ducts. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (D) Higher magnification of the solid part of mammary carcinoma shown in panel C with atypical cells and a few mitotic figures. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (E) Mammary adenocarcinoma showing a tubular growth pattern. Bar. 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (F) Higher magnification of the carcinoma shown in panel E showing both tubular and solid areas. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (G) Well-differentiated mammary adenocarcinoma showing a tubular growth pattern. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (H) Higher magnification of the carcinoma shown in panel G. Bar, 50 μm. (I) Immunostaining for hVEGF-D was positive in the surface of ductular structures. Picture from carcinoma is shown in panels E and F. Bar, 100 μm. The objective lens used was UPlanApo 10×/0.4 Ph1 ∞/0.17 (Olympus). (J) Solid parts of tumor shown in panels E and F showed CK7 immunopositivity. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (K) Increased number of vessels with angiogenic features in mammary adenocarcinoma shown in panels C and D. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (L) Lung with metastases of mammary adenocarcinoma. Original tumor shown in panels E and F. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (M) Higher magnification of the lung metastasis shown in panel L. Note dilated ducts. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (N) Lung papillary adenocarcinoma. Bar, 50 μm. (O) Higher magnification of the adenocarcinoma papillae in tumor shown in panel N. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (P) Positive immunostaining for hVEGF-D in papilla stalk. Note positivity also in vessels at the border of the tumor. Bar, 100 μm. The objective lens used was UPlanApo 10×/0.4 Ph1 ∞/0.17 (Olympus). (Q) Multifocal foci of bronchioloalveolar proliferation in lung adenocarcinoma. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (R) Higher magnification of the bronchioloalveolar proliferation in adenocarcinoma shown in panel R. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (S) Solid growth in skin basal cell carcinoma. Note necrosis. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (T) Higher magnification of the basal cell carcinoma. Note mitosis. Bar, 50 μm. The objective lens used was UPlanApo 20×/0.70 (Olympus). (U) Skin anaplastic carcinoma consists of spindle cells. Bar, 200 μm. The objective lens used was UPlanApo 4×/0.16 ∞/− (Olympus). (V) Higher magnification of the anaplastic carcinoma. Note atypia. Bar, 50 μm. The objective lens used UPlanApo 20×/0.70 (Olympus). (W) Some tumor cells were positive for hVEGF-D immunostaining in an anaplastic carcinoma. Bar, 100 μm. The objective lens used was UPlanApo 10×/0.4 Ph1 ∞/0.17 (Olympus). (X) Increased number of vessels with angiogenic features in an anaplastic carcinoma shown in panels U and V. Bar, 100 μm. The objective lens used was UPlanApo 10×/0.4 Ph1 ∞/0.17 (Olympus).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal